Related Experiment Video
Updated: Aug 8, 2026
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Drug acetylator phenotypes in newborn infants
Biological Research in Pregnancy and Perinatology
|January 1, 1987
Summary
In healthy newborns, the slow acetylator phenotype is predominant (83%), a higher frequency than in other age groups. This finding highlights a potential clinical risk factor in neonates due to increased drug sensitivity.
Area of Science:
- Pharmacogenetics
- Neonatal Medicine
- Drug Metabolism
Background:
- Drug acetylator phenotype influences drug metabolism and efficacy.
- Understanding acetylator phenotype distribution across age groups is crucial for personalized medicine.
- Neonates may exhibit unique metabolic profiles compared to adults.
Purpose of the Study:
- To determine the distribution of drug acetylator phenotypes in healthy newborn infants.
- To compare the frequency of acetylator phenotypes in newborns with other age groups.
- To identify potential factors influencing neonatal acetylator phenotypes.
Main Methods:
- Phenotyping 100 healthy newborn infants using a single oral dose of sulphadimidine (100 mg).
- Assaying total and free sulphadimidine in urine to determine acetylator status.
- Comparing observed phenotype frequencies with data from different age groups.
Main Results:
- The slow acetylator phenotype was predominant in healthy newborns, observed in 83% of infants.
- This frequency was the highest observed across all studied age groups.
- Elderly subjects also showed a predominance of slow acetylators.
Conclusions:
- Neonatal acetylator phenotype is influenced by genetic, environmental, and developmental factors.
- A negative pantothenic acid balance potentially contributes to insufficient Coenzyme-A synthesis and slow acetylation in neonates.
- The predominance of the slow acetylator phenotype in neonates represents a significant clinical risk factor due to heightened drug sensitivity.
Related Concept Videos
01:24Phase II Reactions: Acetylation Reactions
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...